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Cell fusion inhibition requires higher concentrations of inhibitors for HIV-1 and 
HIV-2, than cell free infection.
For HIV-2, Maraviroc was also the best cell fusion inhibitor (IC50= 0.0603 μM) 
and T20 the worst (IC50 of 3.86μM). MPI by P3 was 95% at 1.42 μM, by 
AMD3100 was 45% at 0.80μM, by T1249 was 99.8% at 5μM and by TAK-779 
was 55% at 23.20μM. The NAbs from HIV-2 infected patients we have tested so 
far did not prevent cell fusion. 
We tested several entry inhibitors including the fusion inhibitors T1249, T20
and P3, the CCR5 antagonists Maraviroc and TAK-779, the CXCR4 antagonist
AMD3100 and several neutralizing antibodies. All compounds inhibited HIV-
1 and HIV-2 cell fusion albeit to different levels.
For HIV-1, the best cell fusion inhibitor was Maraviroc with an IC50 of
0.0076μM. T1249 and P3 had IC50s of 0.61μM and 1.34μM, respectively.
TAK-779 was the weakest inhibitor, with an IC50 of 12.64μM. Maximum
percentage of inhibition (MPI) by T20 was 75% at 10.02μM and by
AMD3100 was 61% at 0.80μM. We are currently testing reference NAbs
from HIV-1 infected patients for their cell fusion inhibition activity.
We developed a new method in which Hela-CD4- cells are first transfected
with a Tat expressing plasmid (pcDNA3.1+/Tat101) and infected with
recombinant vaccinia viruses expressing either the HIV-1 (vPE16) or HIV-2
(vSC50) envelope glycoproteins (M.O.I.=1 PFU/cell). The cells are then
added to TZM-bl cells (express the CD4, CCR5 and CCR4 receptors and
luciferase) in the presence of the drugs under analysis at different
concentrations. When cell-to-cell fusion (syncytia) occurs the Tat protein
diffuses to the TZM-bl cells activating the expression of a reporter gene
(luciferase).
Inhibition of HIV cell entry by antiretroviral drugs and neutralizing
antibodies (NAbs) is typically measured in assays where cell-free virions
enter reporter cell lines. However, direct Env-mediated cell-to-cell
transmission is a major mechanism of HIV infection that also needs to be
targeted. In this work we aimed to determine the ability of anti-HIV
compounds in clinical or research use to inhibit HIV mediated cell-to-cell
fusion (syncytia formation).
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• HIV replicates more efficiently and rapidly through direct contact between
cells, and this mode of transmission likely mediates a significant fraction of
viral spread and immune evasion in vivo.
• This form of dissemination appears to be less susceptible to inhibition by
antiretroviral drugs than cell-free virus transmission.
• Fusion and entry inhibitors in clinical use are much more effective at
preventing cell-associated HIV-1 entry than HIV-2.
• Our new method will be useful to quickly identify new drugs and antibodies
that can prevent cell-to-cell HIV-1 and HIV-2 infection.
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Figure 2 – Schematic representation of the novel method used to test cell-to-cell fusion inhibition
Figure 3 - % of inhibition of rVV vPE16 (HIV-1) with different concentrations of inhibitors.
Figure 4 - Percentage of inhibition of vSC50 (HIV-2) with different concentrations of inhibitors
Table 1 – IC50 values for HIV-1 and HIV-2 cell free and cell fusion inhibition of infection
Figure 1 –Microscopic observation of syncytia for untreated Hela and TZM-bl cells. 
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